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Abstract
Background: Bone marrow-derived circulating progenitor cells (BM-CPCs) in patients with coronary heart disease
are impaired with respect to number and mobilization. However, it is unknown whether the mobilization of BM-
CPCs depends on the number of diseased coronary arteries. Therefore, in our study, we analysed the correlation
between the diseased coronary arteries and the frequency of CD34/45+ BM-CPCs in peripheral blood (PB) in
patients with ischemic heart disease (IHD).
Methods: The frequency of CD34/45
+ BM-CPCs was measured by flow cytometry in 120 patients with coronary 1
vessel (IHD1, n = 40), coronary 2 vessel (IHD2, n = 40), coronary 3 vessel disease (IHD3, n = 40) and in a control
group of healthy subjects (n = 40). There was no significant difference of the total number of cardiovascular risk
factors between IHD groups, beside diabetes mellitus (DM), which was significantly higher in IHD3 group
compared to IHD2 and IHD1 groups.
Results: The frequency of CD34/45
+ BM-CPCs was significantly reduced in patients with IHD compared to the
control group (CD34/45
+; p < 0.001). The frequency of BM-CPCs was impaired in patients with IHD3 compared
to IHD1 (CD34/45
+; p < 0.001) and to IHD2 (CD34/45
+; p = 0.001). But there was no significant difference in
frequency of BM-CPCs between the patients with IHD2 and IHD1 (CD34/45
+; p = 0.28). In a subgroup we
observed a significant negative correlation between levels of hemoglobin AIc (HbAIc) and the frequency of BM-
CPCs (CD34/45
+; p < 0.001, r = -0.8).
Conclusions: The frequency of CD34/45
+ BM-CPCs in PB is impaired in patients with IHD. This impairment may
augment with an increased number of diseased coronary arteries. Moreover, the frequency of CD34/45
+ BM-CPCs
in ischemic tissue is further impaired by diabetes in patients with IHD.
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Circulating progenitor cells are primitive bone marrow
(BM) cells that have the capacity to proliferate, migrate
and differentiate into various mature cell types [1,2].
These bone marrow-derived circulating progenitor cells
(BM-CPCs) express unique surface markers, such as
CD34+ and the early hematopoietic cell marker CD133+
(AC133+). During ischaemia, populations of BM-CPCs
are mobilized and recruited to ischaemic areas, accelerat-
ing the neovascularization process [3]. Previous studies
demonstrate that cardiovascular risk factors (CVRFs) for
coronary artery disease correlate with a reduced number
and functional activity of circulating endothelial progeni-
tor cells [4]. Moreover, diabetic patients showed impaired
proangiogenic and colony-forming activity of circulating
progenitor cells [5,6]. However, it is unknown whether
the mobilization of BM-CPCs relates to the number of
diseased coronary arteries in patients with IHD. In this
study, we analysed the frequency of CD34/45
+ BM-CPCs
and their relationship with the number of diseased cor-
onary arteries in patients with ischaemic heart disease
(IHD).
Materials and methods
Study Protocol and Study Population
The study included 120 IHD patients and 40 healthy sub-
jects between 18-80 years of age. We selected a control
g r o u po f4 0h e a l t h ys u b j e c t sw i t h o u to v e r th e a r td i s e a s e
and/or major cardiovascular risk factors (diabetes, smok-
ing, hypertension, hypercholesterolemia, and familial
history). A cardiovascular risk factors (CVRFs) score
including age > 40 years, male sex, hypertension,
diabetes, smoking, positive family history and hypercho-
lesterolemia was calculated according to Vita et al. [7]
Hypertension was defined as a history of hypertension
for > 1 year that required the initiation of antihyperten-
sive therapy by the primary physician. Smoking was
defined as patients revealing a history of smoking for >
two pack-years and current smoking. Positive family his-
tory was defined as documented evidence of coronary
artery disease (CAD) in a parent or sibling before 60
years of age. Hypercholesterolemia was defined as fasting
low-density-lipoprotein (LDL) cholesterol levels exceed-
ing 130 mg/dl. Diabetes was defined as the need for oral
antidiabetic drug therapy or insulin use.
Exclusion criteria were the presence of acutely decom-
pensated heart failure with a New York Heart Association
(NYHA) class of IV, infectious or inflammatory disease,
active bleeding, surgery or trauma within two months,
renal or liver dysfunction, thrombocytopenia, or anaemia,
a severe comorbidity and alcohol or drug dependency, a
history of other severe chronic diseases or cancer, or
unwillingness to participate. The study conforms with the
principles outlined in the Declaration of Helsinki and was
approved by the local ethics committee. Written consent
was obtained from each patient.
Coronary Angiography and Left Ventriculography
All IHD patients underwent left heart catheterization, left
ventriculography and coronary angiography. Cardiac
catheterization was performed according to the guidelines
for coronary angiography of the American College of Car-
diology and the American Heart Association [8]. Cardiac
function was determined by left ventriculography. Cardiac
function was evaluated by global EF. Global Ejection Frac-
tion (EF) was measured with Quantcor software (Siemens,
Erlangen/Germany). The extent of coronary artery disease
was scored by at least two independent interventional car-
diologists as 0 (stenosis < 50 percent), 1 (stenosis of any
main coronary artery > 50 percent), 2 (stenosis of two
main coronary arteries > 50 percent), and 3 (stenosis of
three main coronary arteries > 50 percent).
Frequency of CD34/45
+ BM-CPCs
10 ml peripheral blood (PB) were taken from the study
population to measure of BM-CPCs as well as conduct
biochemical analyses. CD34/45
+ BM-CPCs were quanti-
fied by flow cytometry (EPICS-XL, Beckmann Coulter)
i n5o f1 0m lP Bf r o me a c hs u b j e c t .A s s e s s m e n t si n
IHD patients (n = 120) were done during cardiac cathe-
terization. For the control group (n = 40), measurements
of CD34/45
+ were performed on day 1 of admission. PB
samples were analysed within two hours.
Samples were stained with fluorescein isothiacyanate
(FITC) conjugate of a CD45
+ antibody (clone J33, Coul-
ter/Immunotech, Marseille/France) that detects all iso-
forms and glycoforms of the CD45 family, phycoerythrin
(PE) conjugate of a CD34
+ antibody (clone 581, Coulter/
Immunotech, Marseille/France) that detects a class III
epitope on all glycoforms of the CD34
+ antigen. Control
samples were stained with CD45
+ FITC and an IgG1 PE
(Coulter/Immunotech, Marseille/France) isotype.
For each patient, EDTA blood samples were labeled with
CD34/45
+ and IgG1/CD45. All tubes were incubated at
room temperature in the dark. After incubation, mainly
red blood cells were lysed with ammonium chloride and
washed with phosphate-buffered saline (PBS). Samples
were then stored on ice at 4°C in the dark for 20 min and
analysed by flow cytometry [9,10].
Samples were subjected to a 2D side scatter-fluores-
cence dot plot analysis. After appropriate gating, the con-
centration of BM-CPCs with low cytoplasmic granularity
(low side ward scatter) was quantified and expressed as a
concentration of cells per million white blood cells.
Biochemical Measurements
Serum creatine phosphokinase (CPK) values (normal
range: 24 - 195 U/l), inflammatory markers such as
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leukocytes (normal range: 4 - 12 × 10
3/μl) and routine
l a b o r a t o r yt e s t sw i t hH b A 1 cw e r em e a s u r e di nt h e
remaining 5 of 10 ml PB from each study subject.
Statistical Analysis
Continuous data are presented as mean ± SD. A com-
parison of the distributions of a continuous variable
between two independent groups was performed using
the two-sided nonparametric Mann-Whitney test. The
type I error rate a w a sc h o s e na s5 %a n dt w o - s i d e dp -
values equal or less than 0.05 were interpreted as statis-
tically significant. Some qualitative baseline characteris-
tics were compared using the Fisher’s Exact-Test.
A bivariate regression analysis was presented in a gra-
phical form and Pearson’s correlation coefficient was
obtained.
Statistical significance was accepted, if the corresponding
two-sided p-value was smaller or equal to 0.05. Statistical
analysis was performed with SPSS for Windows (Version
15.0).
Results
Baseline characteristics of the patients and healthy
control subjects
We included 120 patients with IHD and 40 healthy sub-
jects without heart disease in the study. The baseline
characteristics of the study population are depicted in
table 1. Interestingly, there was a significant difference
in the number of DM patients in the IHD3 group com-
pared to groups IHD1 and IHD2. In contrast, there was
no significant difference in the number DM patients
between IHD1 and IHD2. Also, no significant differ-
ences were observed in other baseline characteristics
and demographics of patients between all IHD groups
(table 1).
Frequency of CD34/45
+ BM-CPCs
The frequency of CD34/45
+ BM-CPCs was measured by
f l o wc y t o m e t r yi n1 2 0I H Dp a t i e n t sa sw e l la si n4 0
healthy subjects. The frequency of CD34/45
+ BM-CPCs
was significantly reduced in IHD patients (n = 120)
compared to healthy subjects (n = 40) (CD34/45
+;p<
0.001) (Figure 1). We observed a significant decrease of
CD34/45
+ frequency in patients with IHD3 (n = 40)
compared to IHD1 (n = 40) (CD34/45
+; p < 0.001) and
IHD2 (n = 40) (CD34/45
+; p = 0.001) patients. There
was no significant difference of CD34/45
+ frequency
between IHD1 and IHD2 patients (CD34/45
+;p=0 . 2 8 )
(Figure 2). Additionally, the number of leukocytes by
FACS-analysis as well as by biochemical analysis in each
group were measured to exclude a negative effect of leu-
kocytes on frequency of CD34/45
+ BM-CPCs. There was
no significant difference in the number of leukocytes
Table 1 Baseline clinical characterics of the study population.
IHD1
(n = 40)
IHD 2
(n = 40)
IHD 3
(n = 40)
P Control Group
(n = 40)
Age 60 ± 15 60 ± 11 64 ± 15 NS 64 ± 10
Male 24 26 25 NS 21
Cardiovascular Risk Factors % (n)
Hypertension 80 (n = 32) 80 (n = 32) 78 (n = 31) NS -
Hyperlipidemia 60 (n = 24) 60 (n = 24) 53 (n = 21) NS -
Smoking 68 (n = 27) 75 (n = 30) 63 (n = 25) NS -
Positive family history of CAD 40 (16) 40 (n = 16) 35 (n = 14) NS -
Diabetes 20 (n = 8) 20 (n = 8) 60 (n = 24) p = 0.001 -
OHA 15 (n = 6) 15 (n = 6) 45 (n = 18) NS -
Insulin 5 (n = 2) 5 (n = 2) 15 (n = 6) NS -
Total number of CVRFs 4.2 ± 0.8 4.3 ± 0.8 4.4 ± 0.9 NS -
Infarct-related vessel (LAD/LCX/RCA) 19/8/13 20/10/11 20/8/12 NS -
PTCA/Stent at the time of AMI 40/40 40/40 40/40 NS -
Ejection fraction (%) 45 ± 10 43 ± 11 40 ± 10 NS 69 ± 9
Medication (%) -
Aspirin 100 100 100 NS -
Clopidogrel 100 100 100 NS -
ACE inhibitor or AT II blocker 100 100 100 NS -
Beta-blocker 100 100 100 NS -
Aldosterone Antagonist 25 25 30 NS -
Statin 100 100 100 NS -
Ischemic heart disease (IHD), Oral hypoglycaemic agent (OHA), Coronary artery disease (CAD), Percutaneous transluminal coronary angioplasty (PTCA), Left
anterior descending coronary artery (LAD), Left circumflex artery (LCX), Right coronary artery (RCA), Coronary artery disease (CAD), Cardiovascular risk factors
(CVRFs), Acute myocardial infarction (AMI), None significant (NS).
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3/μl, IHD2; 8 ±
3×1 0
3/μl, 8 ± 2 × 10
3/μl, p = NS)
Relationship between DM and frequency of BM-CPCs in
IHD patients
After we observed that patients with IHD3 had a signifi-
cant higher incidence of DM compared to IHD2 and
IHD1, we investigated the link between a DM and the
frequency of BM-CPCs in IHD patients in a subgroup of
patients. We observed a significant negative correlation
between the levels of HbA1c and the frequency of CD34/
45
+ (p < 0.001 r = -0.8, n = 40) (Figure 3). Moreover, the
BM-CPCs frequency was significantly reduced in DM
patients with HbA1c > 7% (n = 20) compared to DM
patients with HbA1c < 7% (n = 20) (CD34/45
+;
p < 0.001) (Figure 4).
Discussion
In this controlled study we examined the correlation
between the diseased coronary arteries and the fre-
quency of CD34/45+ BM-CPCs in patients with IHD.
Coronary artery disease results from a chronic inflam-
matory disease of the vascular wall and leads to vessel
occlusion and organ damage [11]. Despite intense efforts
Figure 1 The frequency of CD34/45
+ BM-CPCs were significanty reduced a total of IHD patients as compared to healthy subjects.
Figure 2 The frequency of CD34/45
+ BM-CPCs was impaired in patients with IHD3 as compared to IHD1. But there was no significant
difference in frequency of BM-CPCs between the patients with IHD2 and IHD1.
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cess remains poorly understood. Reports suggest that risk
factors and a genetic predisposition together induce
inflammatory processes that leads to cell damage and
impairs regeneration within the vessel wall [12,13]. Since
resident endothelial cells infrequently proliferate, [14] it
has been postulated that there are other sources of
vascular replenishment in response to continuous damage
[15]. Circulating progenitor cells derived from bone mar-
row circulate in the peripheral blood and have been impli-
cated in neoangiogenesis after tissue ischemia has
occurred [16-19]. BM-CPCs are capable of proliferating
and differentiating into endothelial cells and are therefore
ideal candidates for vascular regeneration [20,21].
Figure 3 We observed a significantly inverse correlation between the frequency of CD34/45
+ BM-CPCs and levels of HbA1C in total of
IHD patients with diabetes (n = 40).
Figure 4 The CD34/45
+ BM-CPCs frequency was significanty reduced in a total of DM patients with HbA1C > 7% (n = 20) as
compared to DM patients with HbA1C < 7% (n = 20).
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or mobilization of stem cells and progenitor cells benefi-
cially influences the repair of endothelial cells after injury
and the progression of atherosclerosis [22-28]. Clinical
trials indicated a beneficial effect of intracoronary infusion
of BMCs, or circulating progenitor cells (CPCs), on myo-
cardial function in patients with acute myocardial infarc-
tion (AMI) [29,30]. Previous studies demonstrated, that
the mobilization and functional activity of CD34/45
+ and
CD133/45
+ BM-CPCs significantly increased after an
intracoronary infusion of BMCs in patients with ischemic
heart disease [31,32]. BM-CPCs can also be used as a pre-
dictive biomarker for cardiovascular risk, vascular function
and the extent of cardiac repair [33]. Moreover, smoking
is associated with depletion of CD34+ and CD133+
endothelial progenitor cells in patients with coronary
artery disease [34]. In a large clinical study, Hill et al [35]
reported that high-risk individuals have fewer BM-CPCs
compared with to their low-risk counterparts. In contrast,
Werner et al [11] identified a significant association
between increased numbers of BM-CPCs and a decreased
risk of major cardiovascular events and hospitalization in
patients with coronary artery disease. BM-CPCs mobiliza-
tion can also predict severe endothelial dysfunction in
patients with coronary heart disease [36]. Moreover, the
transient increase in CD34/45
+ and CD133/45
+ BM-CPCs
reached a maximum after three weeks of regular symp-
tom-limited (ischemic and/or subischemic) exercise train-
ing, but did not persist until 3 months after the regular
training after acute myocardial infarction [37,38]. How-
ever, it is unknown whether the frequency of CD34
+ BM-
CPCs relates to the number of diseased coronary arteries
in patients with IHD. We demonstrated in our study that
the frequency of BM-CPCs was significantly impaired in
patients with IHD3 compared to IHD2 and IHD1. In
patients with heart failure and preserved LVEF, diabetes is
associated with a significantly increased risk of developing
adverse HF outcomes [39]. Diabetes mellitus is associated
with both an increased risk of atherosclerotic disease and
poor outcomes after vascular occlusion. The clinical sever-
ity of vascular occlusive disease in diabetics has in part
been attributed to impaired collateral vessel development
[40] Extensive studies have shown that the numbers of cir-
culating angiogenic cells are significantly lower in type II
diabetes and their angiogenic potential is also dramatically
diminished. These cells display defective adhesion to the
endothelium, reduce proliferation rate, and impaire ability
to create new vascular structures [41,42]. Patients with
type 1 diabetes have reduced levels of endothelial progeni-
tor cells and their functional capacity is impaired. Reduced
nitric oxide bioavailability and increased oxidative stress
play a role in endothelial progenitor cell dysfunction in
these patients. Similarly, insulin resistance impairs circu-
lating angiogenic progenitor cell function. On the other
hand, increases in fractalkine level and the number and
functional changes of blood dendritic cells might contri-
bute to diabetic coronary atherosclerosis and plaque desta-
bilization [43-45]. On the basis of these findings, it is
tempting to speculate that the decreased frequency of
CD34
+ BM-CPCs by DM lead to a progression of athero-
sclerosis and increase the number of diseased coronary
arteries in patients with IHD. In line with this hypothesis
we observed in our study a significant higher incidence of
DM in patients with IHD3 compared to IHD2 and IHD1.
Furthermore, we demonstrated that the frequency of BM-
CPCs negatively correlated with the level of HbA1c in
IHD patients with DM. The CD34
+ BM-CPCs frequency
in DM patients with HbA1c > 7% was significantly
reduced compared to DM patients with HbA1c < 7%.
Recent studies have shown that the PPARϒ agonist piogli-
tazone treatment increases the number and function of
BM-CPCs in type 2 DM patients with coronary artery dis-
ease [46,47]. Improved levels of HbA1c by pharmacologi-
cal therapy may lead to an increase of BM-CPCs
frequency and functional activity and thereby may
enhance the vascular regeneration in IHD patients with
DM.
In the present study we could demonstrate that CD34
+
BM-CPCs frequency was impaired in patients with IHD.
This impairment correlates with an increase in the num-
ber of diseased coronary arteries. Moreover, the frequency
of CD34
+ BM-CPCs is further impaired by DM in patients
with IHD.
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